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Abstract
Recurrent community-acquired pneumonia (CAP) requiring hospitalization is a matter of particular concern. However, current information
on its prevalence, aetiology and risk factors is lacking. To address these issues, we performed an observational analysis of a prospective
cohort of hospitalized adults with CAP. Recurrence was deﬁned as two or more episodes of CAP 1 month apart within 3 years. Patients
with severe immunosuppression or local predisposing factors were excluded. Of the 1556 patients, 146 (9.4%) had recurrent CAP. The
most frequent causative organism was Streptococcus pneumoniae, both in patients with recurrent CAP and in those without recurrence.
Haemophilus inﬂuenzae, other Gram-negative bacilli and aspiration pneumonia were more frequent among patients with recurrent CAP,
whereas Legionella pneumophila was rarely identiﬁed in this group. Independent factors associated with recurrent CAP were greater age,
lack of pneumococcal vaccination, chronic obstructive pulmonary disease (COPD) and corticosteroid therapy. In a sub-analysis of 389 epi-
sodes of pneumococcal pneumonia, the only independent risk factor for recurrence was lack of pneumococcal vaccination. Recurrence of
CAP is not a rare clinical problem and it occurs mainly in the elderly, patients with COPD, and those receiving corticosteroids. Our study
provides support for recommending pneumococcal vaccination for adults at risk of pneumonia, including those with a ﬁrst episode of CAP.
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Introduction
Community-acquired pneumonia (CAP) is one of the most
common infections [1]. More than four million adults per year
in the USA present with CAP, and at least 20% of these will
need hospitalization. This represents a substantial societal
burden in terms of mortality, morbidity and economic cost
[2]. The average cost of an episode of CAP in the USA in a
hospitalized patient has been estimated as $6000–7000 [3].
While most patients experience a single episode of CAP,
some have recurrent episodes; in fact, Osler regarded recur-
rence in pneumonia as more common than in any other acute
infectious disease. In the pre-antibiotic era, the incidence
established for recurrent CAP ranged between 13.6% and
22% of episodes. Nevertheless, since the introduction of anti-
biotics and vaccination, recurrent CAP has received scant
attention [4–6].
Clinicians are well aware that aging, cigarette smoking,
heavy alcohol intake, and conditions such as chronic
obstructive pulmonary disease (COPD) predispose to CAP
development [7]. Furthermore, local pulmonary disorders,
conditions predisposing to aspiration, and innate or acquired
immunodeﬁciency are well-known causes of recurrent pneu-
monia [8–10]. This prospective study was designed to deter-
mine the prevalence and aetiology of recurrent CAP, and the
risk factors for recurrence, in a large cohort of hospitalized
adults who were not severely immunosuppressed and who
did not have local predisposing factors.
Methods
Setting, patients, and study design
The study was carried out in a 900-bed university hospital
for adults in Barcelona, which serves an area of 1 100 000
inhabitants and admits approximately 24 000 patients per
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year. In Catalonia, a region in the northeast of Spain with a
population of approximately seven million people, 23-valent
polysaccharide pneumococcal vaccine is recommended for
people aged ‡65 years and in younger persons with medical
conditions that place them at increased risk.
From 1995, all patients with CAP requiring hospitalization
have been prospectively recorded at our institution, and
have been the subject of previous studies [11–15]. In the
present investigation, all non-severely immunosuppressed
adults hospitalized with CAP from January 1, 1995 through
December 31, 2005 were analysed. Patients with neutro-
penia, immunoglobulin deﬁciencies, HIV infection, and those
who underwent transplantation or splenectomy, as well as
those who were receiving immunosuppressant treatment
and/or high-dose corticosteroids (>20 mg/day of prednisone
or its equivalent) were not included. Cases in which the time
elapsed since the initial diagnosis of pneumonia to the
current study was less than 3 years were not included.
Patients who died (£30 days after hospitalization) and those
who had a new episode of CAP requiring hospitalization
<1 month or >3 years after the ﬁrst episode were excluded.
We also excluded patients with local predisposing factors,
including bronchial stenosis or compression, bronchiectasis,
or endoluminal lesions such as foreign bodies or malignancy.
Patients who received a diagnosis of CAP were divided
into two groups: patients who experienced two or more epi-
sodes of pneumonia within a 3-year interval separated by an
asymptomatic period of at least 1-month, and those who did
not have any recurrence requiring a new admission in the
study hospital within 3 years of pneumonia diagnosis. These
groups are referred to as recurrent pneumonia and non-
recurrent pneumonia, respectively. This prospective, longitu-
dinal and observational study was approved by the Ethics
Committee of our institution.
Clinical evaluation and follow-up
At the initial visit, before empirical antibiotic therapy was
started, the clinical history and the results of complete physi-
cal examination were recorded. Two sets of blood samples
were obtained and cultured and, when available, a sputum
sample was evaluated by use of Gram staining and culture.
Urinary antigen detection tests for Streptococcus pneumoniae
and Legionella pneumophila were performed if indicated by the
attending physician. Paired serum samples during the acute
and convalescent phases of infection (separated by a
3–8 week interval) were also obtained for serological studies.
Antibiotic therapy was administered according to the
hospital guidelines, which recommended the administration
of a b-lactam (ceftriaxone or amoxicillin-clavulanate) with or
without a macrolide or a ﬂuoroquinolone. Combination
therapy was recommended for patients with clinical suspicion
of Legionella or an atypical pathogen, or in the absence of a
demonstrative sputum Gram stain. Levoﬂoxacin monothera-
py was allowed for selected cases. Concordance of antibiotic
therapy was examined for all cases with an aetiological diag-
nosis, according to susceptibility test criteria for classical
respiratory pathogens.
Patients were seen daily during their hospital stay by one
or more of the investigators, who provided medical advice
when requested and recorded demographic characteristics,
underlying disease, clinical features, vaccination status, causa-
tive agents, therapy, and outcomes. A long-term follow-up
visit took place 1 month after discharge. Pneumococcal
vaccination was then offered to all unvaccinated patients.
Deﬁnitions
Community-acquired pneumonia was deﬁned as the pres-
ence of a new inﬁltrate on a chest radiograph plus one
or more of the following: fever (temperature ‡ 38.0C)
or hypothermia (temperature < 35.0C), new cough with or
without sputum production, pleuritic chest pain, dyspnea,
and altered breath sounds on auscultation. Tobacco abuse
was recorded when a patient had smoked more than ten
cigarettes per day for at least 1 year preceding the study, as
was alcohol consumption when a patient had consumed
more than 80 g of alcohol daily for at least 1 year preceding
the study.
Vaccination status
Vaccination status was assessed from interview with the
patients or their relatives and review of hospital and
personal health records (vaccination card). A patient was
considered to have been pneumococcal-vaccinated if
23-valent polysaccharide pneumococcal vaccine had been
administered in the 5 years before admission, as documented
in the records of the hospital and primary healthcare centre.
A patient was considered to be inﬂuenza-vaccinated if inﬂu-
enza vaccine had been administered during the year prior to
admission.
Microbiological studies
The investigation of pathogens in blood, normally sterile ﬂu-
ids, sputum and other samples, was performed by standard
microbiological procedures. Streptococcus pneumoniae antigen
in urine was detected by using a rapid immunochromato-
graphic assay (NOW assay; Binax Inc, Portland, Maine, USA).
Legionella pneumophila serogroup 1 antigen in urine was
detected by an immunochromatographic method (NOW
Legionella Urinary Antigen Test; Binax Inc). Standard serologi-
cal methods were used to determine antibodies against the
1034 Clinical Microbiology and Infection, Volume 15 Number 11, November 2009 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 1033–1038
following pathogens: Mycoplasma pneumoniae (indirect aggluti-
nation), Chlamydophila psittacci (immunoﬂuorescence [IF]),
Chlamydophila pneumoniae (micro-IF), Coxiella burnetii (IF),
L. pneumophila (serogroups 1–6) (enzyme immuno assay
[EIA]), respiratory syncytial virus (EIA), parainﬂuenza 3 virus
(EIA), and inﬂuenza A virus (EIA).
Aetiological diagnosis
An aetiological diagnosis was considered deﬁnitive in the
following situations: isolation of a respiratory pathogen in a
usually sterile specimen, isolation of L. pneumophila in spu-
tum, detection of L. pneumophila serogroup 1 or pneumo-
coccal antigen in urine, four-fold increase in the antibody
titre, or seroconversion, for atypical pathogens. An aetio-
logical diagnosis was considered presumptive when a pre-
dominant microorganism was isolated from a purulent
sample (presence of >25 polymorphonuclear leukocytes and
<ten squamous cells per low-power ﬁeld [original magniﬁca-
tion ·10]) with compatible Gram stain ﬁndings [11]. Pre-
sumptive aspiration pneumonia was diagnosed on a clinical
and radiological basis in patients who had risk factors such
as compromised consciousness, altered gag reﬂex, dyspha-
gia, severe periodontal disease, putrid sputum, and radio-
graphic evidence of involvement of a dependent pulmonary
segment or necrotizing pneumonia. Cases that did not meet
any of the above criteria were considered pneumonias of
unknown aetiology.
Statistical analysis
To detect signiﬁcant differences between groups (non-recur-
rent pneumonia and recurrent pneumonia), we used the chi-
square or Fisher exact test for categorical variables, and the
Student’s t test or the Mann–Whitney U test for continuous
variables, when appropriate. The multivariate analysis of fac-
tors potentially associated with recurrent pneumonia
included all the signiﬁcant variables identiﬁed in the univariate
analysis considered to be clinically relevant. We used the
step-wise logistic-regression model of the SPSS software pack-
age (SPSS, version 13.5; SPSS Inc, Chicago, IL, USA). Statistical
signiﬁcance was established at a = 0.05. All reported p values
are 2-tailed.
Results
During the study period, 2017 consecutive adults with pneu-
monia were hospitalized. Of these, 169 (8.4%) died after the
ﬁrst episode of CAP, 140 (5.4%) had local predisposing fac-
tors, 127 (6.9%) had immunosuppression, and 25 (1.2%) had
a recurrence in the ﬁrst month or more than 3 years after
the ﬁrst episode. All these patients were excluded. Of the
1556 patients ﬁnally included, 146 (9.4%) had recurrent CAP.
Eighty-one patients had one episode of recurrence, 53 two
episodes, 11 three, and one patient four episodes of recur-
rence, giving a total of 224 episodes of pneumonia. Most
recurrences (60.4%) occurred within the ﬁrst year. A total
of 1410 patients had no recurrence requiring a new admis-
sion to the study hospital within 3 years of pneumonia diag-
nosis.
Clinical features of the patients according to the study
group (recurrent pneumonia and non-recurrent pneumonia)
are shown in Table 1. When the two groups are compared
it can be seen that patients with recurrent pneumonia were
signiﬁcantly older, more frequently had COPD, and had
more commonly received corticosteroid therapy (at a
lower dosage than that requiring exclusion from the investi-
gation). Recurrence was more frequently observed among
patients in whom the ﬁrst episode of CAP was classiﬁed
into high severity risk classes (IV-V) rather than into low
severity risk classes. Lack of pneumococcal vaccination was
more common in patients with recurrent pneumonia,
whereas the rate of inﬂuenza vaccination was higher in this
group.
A total of 740 (47.6%) of the 1556 patients had not
received pneumococcal vaccination in the 5 years before
admission. The mean age of unvaccinated patients was 62.11
(±19.3) years and 520 (70.3%) of them had underlying
TABLE 1. Patient characteristics
Characteristic
Recurrent
pneumonia
(n = 146)
Non-
recurrent
pneumonia
(n = 1410)
pNo. % No. %
Demographics
Age, years (mean, SD) 70.96 ± 13.824 65.03 ± 16.573 <0.001
Older than 65 years 111 76.0 812 57.6 <0.001
Male, sex 106 72.6 961 68.2 0.348
Vaccination status
Inﬂuenza vaccination 79 54.1 550 39.0 <0.001
Pneumococcal vaccination 58 39.7 758 53.6 0.007
Tobacco abuse 28 19.2 378 26.8 0.071
Heavy alcohol consumption 18 12.3 245 17.4 0.161
Underlying disease 134 91.8 1008 71.5 <0.001
COPDa 56 38.4 354 25.1 <0.001
Diabetes mellitus 26 17.8 239 16.9 0.640
Cancer 17 11.6 108 7.6 0.072
Cerebrovascular disease 7 4.8 45 3.2 0.248
Chronic heart disease 43 29.5 324 23.0 0.079
Chronic renal disease 5 3.4 45 3.2 0.782
Chronic liver disease 9 6.2 74 5.2 0.551
Dementia 9 6.2 51 3.6 0.102
Others 27 18.5 202 14.3 0.178
Corticosteroids (£20 mg/day) 16 11.0 71 5.0 0.007
High risk pneumoniab 91 62.3 732 51.9 0.014
aCOPD, chronic obstructive pulmonary disease.
bPneumonia severity index, >90 points (i.e., risk classes IV and V).
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diseases. According to current guidelines, 652 (88.1%) of
the 740 unvaccinated patients had one or more criteria for
vaccination. Regarding the 88 unvaccinated patients with
recurrent CAP, 64 (72.7%) of them had criteria for vaccina-
tion at the time of the ﬁrst episode of CAP.
An aetiological diagnosis was established in 689 (48.8%)
patients with a single episode of CAP and in 125 (55.8%) of
224 episodes of recurrent pneumonia. As shown in Table 2,
the most frequent causative organism was S. pneumoniae in
both groups. Haemophilus inﬂuenzae, aspiration pneumonia,
and Gram-negative bacilli were more frequently documented
as causative organisms in patients with recurrent pneumonia,
whereas L. pneumophila was only rarely identiﬁed in this
group. No signiﬁcant differences were observed as regards
atypical agents and pneumonia of unknown aetiology. The
overall incidence of bacteraemia was similar in both groups
(10.9% vs. 9.1%, respectively).
No signiﬁcant differences were found regarding the
mean ± SD time to institution of initial antibiotic therapy
(door-to-needle time) between groups (5.89 ± 3.35 vs.
5.08 ± 2.09 h; p 0.339). Concordance of antibiotic therapy
could be determined in 675 CAP episodes. The percentage
of patients receiving discordant empirical antibiotic therapy
was similar in both groups (4.4% vs. 4.9%; p 0.775).
Table 3 summarizes the results of the univariate and mul-
tivariate analyses of factors potentially associated with recur-
rent pneumonia. After adjustment, the only variables
independently associated with recurrent pneumonia in the
multivariate analysis were age over 65 years, lack of pneumo-
coccal vaccination, COPD, and corticosteroid therapy. In a
subanalysis of the 389 episodes of pneumococcal pneumonia
(Table 4), the only independent risk factor for recurrence
was lack of pneumococcal vaccination (OR 2.671 [95% CI
1.404–5.083]).
TABLE 2. Aetiology in 1634 episodes of community-acquired pneumonia
Aetiology
Recurrent pneumonia (n = 224 episodes) Non-recurrent pneumonia (n = 1410 episodes)
p
Presumptive
diagnosis
Deﬁnitive
diagnosis
Total
no. %a
Presumptive
diagnosis
Deﬁnitive
diagnosis
Total
no. %a
Streptococcus pneumoniae 22 41 63 28.1 158 208 366 26.0 0.493
Pneumococcal bacteremia – 16 16 7.2 – 110 110 7.8 0.892
Legionella pneumophila – 4 4 1.8 – 104 104 7.4 0.001
Haemophilus inﬂuenzae 18 6 24 10.8 72 13 85 6.0 0.013
Aspiration pneumoniab 21 2 23 10.3 71 9 80 5.7 0.011
Gram-negative bacilli 2 4 6 2.7 9 3 12 0.9 0.014
Pseudomonas sp. 2 2 4 5 1 6
Escherichia coli – 2 2 1 1 2
Klebsiella pneumoniae – – – 3 – 3
Enterobacter sp. – – – – 1 1
Atypical agents – 7 7 3.1 – 75 75 5.3 0.113
Chlamydophila pneumoniae – 3 3 – 29 29
Chlamydophila psittaci – 2 2 – 15 15
Mycoplasma pneumoniae – 2 2 – 16 16
Coxiella burnetii – – – – 15 15
Virusc – – – – – 5 5 0.4 0.482
Others 3 5 8 3.6 20 22 42 3.0 0.632
Unknown – – 99 44.2 – – 721 51.1 0.054
aPercentages total more than 100% owing to ten patients (4.5%) with recurrent CAP and 47 patients (3.3%) with non-recurrent pneumonia who had mixed pneumonias.
bStreptococcus anginosus group (n = 6), Enterobacter cloacae (n = 2), Eubacterium lentum (n = 1), Prevotella bivia (n = 1), and Porphyromonas asaccharolytica (n = 1) were isolated
from pleural ﬂuid.
cRespiratory syncytial virus (n = 3), parainﬂuenza 3 virus (n = 1), inﬂuenza A virus (n = 1).
TABLE 3. Risk factors associated with recurrent pneumonia
by univariate and multivariate analyses
Univariate analysis
Odds ratio (95% CI)
Multivariate analysis
Odds ratio (95% CI)
Age >65 years 2.352 (1.579–3.504) 2.182 (1.370–3.475)
Male sex 1.197 (0.846–1.694) 0.762 (0.499–1.164)
Lack of pneumococcal
vaccination
1.634 (1.148–2.325) 1.909 (1.302–2.798)
Lack of inﬂuenza
vaccination
2.000 (1.391–2.876) 2.379 (0.991–2.268)
COPD 1.922 (1.344–2.748) 1.534 (1.021–2.303)
Corticosteroid therapy
(£20 mg/day)
2.323 (1.312–4.115) 1.971 (1.047–3.713)
CI, conﬁdence interval, COPD, chronic obstructive pulmonary disease.
TABLE 4. Risk factors associated with recurrent pneumo-
coccal pneumonia by univariate and multivariate analyses
Odds ratio (95% CI)
Univariate analysis
Odds ratio (95% CI)
Multivariate analysis
Age >65 years 2.003 (0.955–4.200) 1.444 (0.678–3.073)
Male sex 0.489 (0.227–1.053) 0.485 (0.221–1.067)
Lack of pneumococcal
vaccination
3.193 (1.625–6.272) 2.671 (1.404–5.083)
Lack of inﬂuenza
vaccination
1.850 (0.954–3.586) 1.973 (0.979–3.978)
COPD 1.550 (0.798–3.012) 1.434 (0.733–2.805)
CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease.
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Discussion
This prospective study shows that recurrence of CAP
requiring hospitalization is a commonly encountered prob-
lem in clinical practice, even among patients without
severe immunosuppression and local pulmonary predispos-
ing factors. Our prevalence of recurrence was 9.4%. The
higher ﬁgures reported by other investigators, ranging from
13.6% to 22%, may be attributable to differences in the
population analysed and the study methods used [4–6]. In
particular, it should be noted that most previous studies
regarding recurrent CAP included immunosuppressed hosts
and patients with pulmonary architectural abnormalities
[16].
The aetiology of recurrent and non-recurrent CAP has
not been compared in previous studies [4–6]. As expected,
we found that S. pneumoniae was the most frequent causative
organism both in patients with recurrent CAP and in those
without recurrences. In our study, H. inﬂuenzae, Gram-nega-
tive bacilli and aspiration pneumonia were more frequent
among patients with recurrent CAP. These aetiologies corre-
late with the conditions found to be associated with recur-
rences in the present study. In this regard, it is well known
that H. inﬂuenzae is particularly frequent among patients with
COPD [17,18]. Moreover, other Gram-negative bacilli are
usually encountered in elderly patients in poor clinical condi-
tion and among those with advanced COPD receiving antibi-
otics and corticosteroid treatment [13,19]. Aspiration
pneumonia mainly occurs in frail older patients with cerebro-
vascular diseases and impaired consciousness. Patients with
these conditions frequently have difﬁculty swallowing and are
more prone to repeated episodes of aspiration and subse-
quent pneumonia [20]. On the other hand, Legionella spp.
have rarely been identiﬁed as a cause of recurrent CAP. In
fact, the occurrence of legionellosis is mainly linked to the
sporadic exposure to exogenous sources [14].
In our study, independent factors associated with recur-
rent CAP were greater age (>65 years), lack of pneumococ-
cal vaccination, COPD, and corticosteroid therapy. Other
investigators [4,6] have also identiﬁed some of these risk fac-
tors. Age and COPD were found to be associated with
recurrence in a previous study of 171 episodes of CAP
occurring in 115 patients aged 50–85 years [6]. In a time-
honoured study involving 158 adult patients seen over a
11-year period, Winterbauer et al. [4] identiﬁed alcoholism,
COPD, congestive heart failure, and diabetes mellitus as pre-
disposing illnesses for recurrent CAP.
Signiﬁcantly, we found lack of pneumococcal vaccination
to be an independent risk factor for recurrent CAP in
general and for the subgroup of patients with pneumococcal
pneumonia in particular. Although the 23-valent polysaccha-
ride pneumococcal vaccine is recommended for use in many
countries [21,22], current vaccination rates among target
adults remain low [23,24]. In a study of Medicare inpatients
with pneumonia conducted by the CDC, the opportunity to
provide pneumococcal vaccine was missed in up to 80% of
those hospitalized at any time during the year, despite the
clear indications for vaccination [25]. Indeed, despite data
demonstrating its safety, low cost, and efﬁcacy in preventing
invasive disease, not all physicians are persuaded of the vac-
cine’s merits [26]. Interestingly, recent studies have shown
that prior pneumococcal vaccination is associated with better
clinical outcomes among hospitalized patients with pneumo-
nia [15,27,28]. Further studies are warranted to determine
whether administering pneumococcal vaccination after an
episode of pneumonia will prevent recurrence.
Our study has some limitations. First, we focused on
recurrent pneumonias admitted to one institution. There-
fore, we cannot rule out the possibility that some patients
with more than one episode of pneumonia could have been
admitted to other hospitals or managed in the outpatient
setting. Secondly, we do not have information regarding
possible episodes of CAP occurring before our study
began. Thirdly, the possible role of polymorphisms of
innate immunity in recurrence was not investigated.
Although few data are currently available regarding the
importance of differences in the genetics of innate immu-
nity and susceptibility to infection, one hypothesis is that
certain polymorphisms in innate immunity molecules may
predispose to recurrence [29]. Investigating the relationship
between immune system genetics and the risk of infection,
recurrence, and prognosis should therefore be a major
focus of future research.
In summary, recurrence of CAP requiring hospitalization
is not a rare clinical problem, even among patients without
severe immunosuppression or local pulmonary predisposing
factors. It occurs mainly among the elderly, patients with
COPD, and those receiving corticosteroids. Our study pro-
vides additional support for recommending pneumococcal
vaccination for adults at risk of pneumonia, including those
with a ﬁrst episode of CAP.
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